Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Open accessThe DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
The vasculature is a key player and regulatory component in the multicellular microenvironment of solid tumors and, consequently, a therapeutic target. In colorectal carcinoma (CRC), antiangiogenic treatment was approved almost 20 years ago, but there are still no valid predictors of response. In addition, treatment resistance has become a problem. Vascular heterogeneity and plasticity due to species-, organ-, and milieu-dependent phenotypic and functional differences of blood vascular cells reduced the hope of being able to apply a standard approach of antiangiogenic therapy to all patients. In addition, the pathological vasculature in CRC is characterized by heterogeneous perfusion, impaired barrier function, immunosuppressive endothelial cell anergy, and metabolic competition-induced microenvironmental stress. Only recently, angiocrine proteins have been identified that are specifically released from vascular cells and can regulate tumor initiation and progression in an autocrine and paracrine manner. In this review, we summarize the history and current strategies for applying antiangiogenic treatment and discuss the associated challenges and opportunities, including normalizing the tumor vasculature, modulating milieu-dependent vascular heterogeneity, and targeting functions of angiocrine proteins. These new strategies could open perspectives for future vascular-targeted and patient-tailored therapy selection in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Different types of vessels are present in human colorectal cancer tissues. In human CRC, blood vessels can be labeled using the markers CD31 or vWF. Lymphatic vessels may be stained with LYVE-1 or podoplanin. Arteries and veins can be differentiated by labeling using the artery marker ephrinB2. This may be complemented by morphological differentiation of arteries (A) and veins (V) together with analysis of milieu-dependent expression of vessel markers such as SPARCL1. CD31, vWF, LYVE-1 and podoplanin panels: 25x objective; ephrinB2 and SPARCL1 panels: scale bars corresponding to 50 µm. The vWF panel is modified from Schellerer et al., Lab Invest 2007 [97].](https://figures.cochat.ai/paper-figures/1940b3d38be94f6e8167c8cad8a8a2b7/blood-vessel-targeted-therapy-in-colorectal-cancer-current-strategies-and-future-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since anti-angiogenic therapies lead to only modest increases in survival for CRC patients”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [211]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Anti-angiogenic therapies, which inhibit the growth of new blood vessels, are currently given in combination with chemotherapy to treat patients with advanced or metastatic CRC [211].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…15 years ago, it became clear that not only tumor cells alone but also the interplay of tumor cells with the different cell types in the surrounding stroma mediated by many different cytokines and growth factors is a paramount denominator of tumor progression and therapeutic responses [5].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 4×
“Unfortunately, as detailed in the previous section, antiangiogenic treatment combined with chemotherapy causes only mild increases in survival, low response rates and moderate efficacy [19].”
BackgroundInfluentialTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“His hypothesis was that vessels are needed for the delivery of nutrients to tumor cells and that blocking vessel growth into tumors may consequently reduce tumor progression [6].”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Disease-and patient-dependent heterogeneity of tumor endothelial cells has clearly been demonstrated by multiregion sequencing of renal carcinoma [92], and this approach may similarly apply to CRC.”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This results in the restoration of vascular maturation, increased capacity to sustain tissue pressure and normalization of the basement membrane [75].”
BackgroundEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 2×
“These inhibitors were named angiostatin, a cleavage product of the blood protein plasminogen involved in fibrolyis, and endostatin, a cleavage product of the extracellular matrix protein collagen XVIII [13,14].”
BackgroundO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345 · cited 2×
“These inhibitors were named angiostatin, a cleavage product of the blood protein plasminogen involved in fibrolyis, and endostatin, a cleavage product of the extracellular matrix protein collagen XVIII [13,14].”
BackgroundSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · cited 1×
“Sidedness was also addressed in a retrospective subgroup analysis of the two pivotal first-line bevacizumab trials of Hurwitz et al. (2004) [19] and Saltz et al. (2008) [37] mentioned above.”
BackgroundGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 2×
“Regorafenib had a statistically significant, but only moderate, effect on OS (6.4 vs. 5.0 months) as monotherapy for chemorefractory patients with mCRC compared to placebo in the phase III multicenter CORRECT trial [25].”
BackgroundInfluentialVEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302047 · Cited by 2,894
Research works printed but not linked: 1
- Vincent, S.H., De Vita, T., and Rosenberg, S.A. (2001). Antiangiogenesis Agents, in Cancer: Principles and Practice of Oncology, Lippincott Williams & Wilkins Publishers.
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“However, since anti-angiogenic therapies lead to only modest increases in survival for CRC patients, there is a need for biomarkers for patient stratification, integration of novel combinations of anti-angiogenic drugs with immunotherapy, and better preclinical models of metastatic CRC [211].”
Ma, J., Yuan, H., Zhang, J., Sun, X., Yi, L., Li, W., Li, Z., Fu, C., Zheng, L., Xu, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.001 · Cited by 39
Rahman, M. A., & Ali, M. M. (2024) · Cancers · doi:10.3390/cancers16172975 · Cited by 28
“Antiangiogenic therapies specifically focus on the endothelial cells of recently developed blood vessels with the goal of interrupting the blood flow to the tumor [67].”
BackgroundJordan, A. M., Drake, R. J. G., & Hodivala‐Dilke, K. (2025) · Physiological Reviews · doi:10.1152/physrev.00046.2024 · Cited by 31
Molecular insights into the role of tumor-specific endothelial cells in metastasis
Taher, T. Z., Kheirkhah, A. H., Mehri, S., Mahmoudian, O., Atashi, S., & Kavianpour, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104964 · Cited by 7
Metadata
- Authors
- Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Naschberger, Elisabeth
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-02-22
- Volume
- 16
- Issue
- 5
- Pages
- 890
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10930912
- OpenAlex
- W4392101799
- Cited by
- 11
- References
- 123
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 2
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- German Research Foundation (DFG) FOR 2438, subproject 2 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG SFB/TRR 241, subproject A06 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG STU 238/10-1 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG TRR 305, subproject B08 (280163318, 375876048, 437201724, 429280966, 493624887)
- DFG-NOTICE program (280163318, 375876048, 437201724, 429280966, 493624887)
- W. Lutz Stiftung (280163318, 375876048, 437201724, 429280966, 493624887)
- Forschungsstiftung Medizin am Universitätsklinikum Erlangen (280163318, 375876048, 437201724, 429280966, 493624887)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, anti-angiogenic therapy, tumor vasculature, vascular heterogeneity, tumor microenvironment, vascular normalization, treatment resistance, predictive biomarkers, vascular-targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. https://app.cochat.ai/papers/10.3390/cancers16050890
- The paper
- Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024). Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. Cancers. https://doi.org/10.3390/cancers16050890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.